The effect of an interleukin‐1 receptor antagonist protein on type ii collagen–induced arthritis and antigen‐induced arthritis in mice
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objective. To investigate the anti‐arthritic effect of recombinant human interleukin‐1 receptor antagonist protein (IRAP) in two experimental models of arthritis. Methods. Recombinant IRAP was administered daily to mice with type II collagen–induced arthritis (CIA) or with antigen‐induced arthritis (AIA) provoked by methylated bovine serum albumin (mBSA). Disease incidence and severity were assessed by a clinical index and histologic features. Serum antibody to type II collagen, spleen cell proliferation to mBSA, and anti‐IRAP antibodies were measured as indices of immune function. Results. IRAP reduced the incidence and delayed the onset of CIA and suppressed the antibody response to type II collagen. In contrast, IRAP did not affect the pathogenesis of AIA and had no effect on either humoral or cellular immune responses to mBSA in arthritic mice. Conclusion. These observations suggest that interleukin‐1 may play a prominent role in the development of some, but not all, forms of arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., & Thompson, R. C. (1990) · Nature · doi:10.1038/343336a0 · Cited by 1,122
Carter, D. B., Deibel, M. R., Dunn, C. J., Tomich, C.-S. C., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., et al. (1990) · Nature · doi:10.1038/344633a0 · Cited by 601
Self-citation
Cited by
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2 · Cited by 981
Arend, W. P., & Dayer, J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380202 · Cited by 891
Structure and mechanism of interleukin-lβ converting enzyme
Wilson, K. P., Black, J.-A. F., Thomson, J. A., Kim, E. E., Griffith, J. P., Navia, M. A., Murcko, M. A., Chambers, S. P., Aldape, R. A., Raybuck, S. A., et al. (1994) · Nature · doi:10.1038/370270a0 · Cited by 847
The balance between IL-1 and IL-1Ra in disease
Arend, W. P. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00020-5 · Cited by 721
Interleukin 6 is required for the development of collagen-induced arthritis
Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De Benedetti, F., Poli, V., & Ciliberto, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.461 · Cited by 604
“Taken together, our results demonstrate that a given cytokine can have varying relevance in different arthritis models, further corroborating previous observations showing different effects of the neutralization of TNF-a in CIA or streptococcal cell wall– induced arthritis (46), and of the IL-1 receptor antagonist in…”
Result(2008) · Arthritis & Rheumatism · doi:10.1002/art.23363 · Cited by 505
Joosten, L. A. B., Helsen, M. M. A., Saxne, T., van de Loo, F. A. J., Heinegård, D., & van den Berg, W. B. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.5049 · Cited by 405
Joosten, L. A. B., Helsen, M. M. A., van de Loo, F. A. J., & van den Berg, W. B. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390513 · Cited by 400
Loo, F. A. J. V. D., Joosten, L. A. B., Van Lent, P. L. E. M., Arntz, O. J., & Van Den Berg, W. B. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380204 · Cited by 380
Anti-Cytokine Therapy for Rheumatoid Arthritis
Maini, R. N., & Taylor, P. C. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.207 · Cited by 376
Caron, J. P., Fernandes, J. C., Martel‐Pelletier, J., Tardif, G., Mineau, F., Geng, C., & Pelletier, J. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390914 · Cited by 366
Cytokine traps: multi-component, high-affinity blockers of cytokine action
Economides, A. N., Carpenter, L. R., Rudge, J. S., Wong, V., Koehler-Stec, E. M., Hartnett, C., Pyles, E. A., Xu, X., Daly, T. J., Young, M. R., et al. (2003) · Nature Medicine · doi:10.1038/nm811 · Cited by 359
Critical Roles for Interleukin 1 and Tumor Necrosis Factor α in Antibody-induced Arthritis
Ji, H., Pettit, A., Ohmura, K., Ortiz-Lopez, A., Duchatelle, V., Degott, C., Gravallese, E., Mathis, D., & Benoist, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020439 · Cited by 332
Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein.
Gabay, C., Smith, M. F., Eidlen, D., & Arend, W. P. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119488 · Cited by 319
Collagen-induced arthritis, an animal model of autoimmunity
Myers, L. K., Rosloniec, E. F., Cremer, M. A., & Kang, A. H. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00480-3 · Cited by 316
Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis.
Griffiths, R. J., Pettipher, E. R., Koch, K., Farrell, C. A., Breslow, R., Conklyn, M. J., Smith, M. A., Hackman, B. C., Wimberly, D. J., & Milici, A. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.2.517 · Cited by 315
Animal models, rheumatoid arthritis
(2011) · SpringerReference · doi:10.1007/springerreference_37459 · Cited by 296
Animal models of arthritis: relevance to human disease.
Bendele, A., Mccomb, J., Gould, T., Mcabee, T., Sennello, G., Chlipala, E., & Guy, M. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700125 · Cited by 293
Kasama, T., Strieter, R. M., Lukacs, N. W., Lincoln, P. M., Burdick, M. D., & Kunkel, S. L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117993 · Cited by 270
RETRACTED: Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation
Cuzzocrea, S., Chatterjee, P. K., Mazzon, E., Dugo, L., Serraino, I., Britti, D., Mazzullo, G., Caputi, A. P., & Thiemermann, C. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704463 · Cited by 209
“There is good evidence that TNFa and IL-1b help to propagate the extension of a local or systemic in¯ammatory process (Henderson & Pettipher, 1989; Piguet et al., 1992; Saklatvala, 1986; Wooley et al., 1993).”
BackgroundRetractedCrew, K. D., Capodice, J. L., Greenlee, H., Apollo, A., Jacobson, J. S., Raptis, G., Blozie, K., Sierra, A., & Hershman, D. L. (2007) · Journal of Cancer Survivorship · doi:10.1007/s11764-007-0034-x · Cited by 87
Cartmell, T., Luheshi, G. N., Hopkins, S. J., Rothwell, N. J., & Poole, S. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.0171j.x · Cited by 62
Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development
Sardar, S., & Andersson, Å. (2016) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1125917 · Cited by 50
Metadata
- Authors
- Wooley, P. H., Whalen, J. D., Chapman, D. L., Berger, A. E., Richard, K. A., Aspar, D. G., & Staite, N. D.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1993-09
- Volume
- 36
- Issue
- 9
- Pages
- 1305-1314
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2128938421
- Cited by
- 204
- References
- 2
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.